Skip to main content
Caplight Logo









Eumentis Therapeutics Inc.

Eumentis Therapeutics Inc.

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://eumentistx.com/

Last Round

Debt

Jun 26, 2024

Total Funding Raised

$36.17M

Company Overview

Eumentis Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops novel therapeutics for the treatment of neuropsychiatric and neurodevelopmental disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug discoveryCNS disorderssmall-molecule therapyPDE10A inhibitorneuropsychiatric disordersclinical-stage biotechNMDA receptor antagonistneurodevelopmental disordersdrug licensingbiotech pipelinecentral nervous systemCNSschizophrenia treatmentautism therapeutics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Eumentis Therapeutics Inc. Comparables

Compare Eumentis Therapeutics Inc. with similar companies based on industry and business-model similarity.

Eumentis Therapeutics Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Noema Pharma
82%
Merck & Co., Inc.
79%
Celon Pharma
78%

Eumentis Therapeutics Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
DebtJun 26, 2024
Series BFeb 15, 2023
GrantFeb 8, 2023
DebtApr 15, 2022
Series AOct 27, 2020
Seed
Sep 2, 2020

Eumentis Therapeutics Inc. Investors

Notable investors and investment history

Eumentis Therapeutics Inc. investors
InvestorRounds
United States Department of DefenseGrant
Joyance PartnersSeed
Social StartsSeed
TCA Venture GroupSeries A, Seed
Life Science AngelsSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 26, 2024

    $765K raised in debt financing.

  • Feb 8, 2023

    $3M grant from the United States Department of Defense.

Eumentis Therapeutics Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Eumentis Therapeutics Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Eumentis Therapeutics Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range8
Year Founded2019
Last FundingJun 26, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.